4 Largecap Revenue Growth Above Long-Term Average Stocks to Watch for Future Multibagger Potential: Adani Ports, Divi’s Labs, Torrent Pharma and Polycab
- October 29, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
Adani Ports Rs 1,761.30. Divi’s Labs Rs 9,558.50. Torrent Pharma Rs 4,557. Polycab Rs 7,680. Market caps from Rs 1.24 lakh crore to Rs 4.05 lakh crore. Data as of 28 Oct 2026.
Quick Answer
Adani Ports, Divi’s Labs, Torrent Pharma and Polycab are the 4 picks in this revenue growth above long-term average stocks watchlist, with market caps between Rs 1.24 lakh crore and Rs 4.05 lakh crore. Adani Ports stands out for the lowest PE of the group at 30.89, while Divi’s Labs offers the strongest latest-quarter profit growth at 65.50%. PE ratios run from 30.89 to 85.60, so compare each one with its industry PE before investing. All figures are as of 28 October 2026.
Revenue growth above long-term average stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Adani Ports, Divi’s Labs, Torrent Pharma and Polycab meet that test, with market caps from Rs 1.24 lakh crore to Rs 4.05 lakh crore and Adani Ports offering the lowest PE of the group at 30.89. Each of these companies has FY26 revenue growth at least 3 percentage points above its FY22 to FY26 compound annual growth rate, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.
This list covers companies with FY26 revenue growth at least 3 percentage points above its FY22 to FY26 compound annual growth rate, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening revenue growth above long-term average stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 28 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Revenue Growth Above Long-Term Average Stocks and Why Do They Attract Multibagger Interest?
Revenue growth above long-term average stocks are shares of large companies whose sales grew faster in FY26 than the average pace of the last four years, a sign that demand is rising. The four here cover ports, pharmaceutical ingredients, pharmaceuticals and cables.
Sales that grow faster than their own long term average point to rising demand and a widening customer base, and rising profit shows that the extra sales are paying off. For revenue growth above long-term average stocks, both FY26 and the latest quarter showed growth. Whichever way you read revenue growth above long-term average stocks, the common thread is rising profit backed by complete financial data. With revenue growth above long-term average stocks, comparing valuation, growth and balance sheet strength together works better than relying on one number. Every company in the table below passed a rising-profit check, and the figures for revenue growth above long-term average stocks are complete. Read each company’s latest results and exchange filings before acting on revenue growth above long-term average stocks.
Revenue Growth Above Long-Term Average Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 28 October 2026. Adani Ports has the lowest PE of the group at 30.89, while Torrent Pharma posts the highest return on equity at 25.49%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Adani Ports and Special Economic Zone | 1,761.30 | 4,05,286 | 30.89 | 31.83 | 13.32% | 0.66 | 1,292.00 to 1,891.10 |
| Divi’s Laboratories | 9,558.50 | 2,50,368 | 85.60 | 36.42 | 15.32% | 0.00 | 5,647.50 to 9,740.00 |
| Torrent Pharmaceuticals | 4,557 | 1,72,983 | 80.23 | 36.42 | 25.49% | 1.79 | 3,480.60 to 5,250.00 |
| Polycab India | 7,680 | 1,23,928 | 42.66 | 49.96 | 22.25% | 0.02 | 6,663.00 to 10,126.00 |
Adani Ports: 26.74% Profit CAGR Since FY22
Adani Ports and Special Economic Zone is India’s largest private port operator, with ports on both coasts and a growing logistics business. It reported FY26 revenue of Rs 40,854.36 crore, up 26.16% year on year, and net profit of Rs 12,782.03 crore, up 15.56%. Net profit has compounded at 26.74% a year since FY22, while revenue has grown 20.55% a year. Operating margin was 64.59% in FY26.
In the June 2026 quarter, revenue rose 23.90% to Rs 11,673.71 crore and net profit grew 10.24% to Rs 3,649.50 crore. The share price has gained 115.30% over five years and 17.95% over the past year. Foreign investors raised their holding from 13.61% in September 2025 to 15.95% in September 2026. The stock trades at a PE of 30.89 against an industry PE of 31.83, below the sector average, with a return on equity of 13.32%.
Divi’s Labs: Debt-to-Equity of 0.00
Divi’s Laboratories makes active pharmaceutical ingredients and intermediates and runs a large custom synthesis business for global drug companies. It reported FY26 revenue of Rs 11,067 crore, up 13.95% year on year, and net profit of Rs 2,568 crore, up 17.21%. Revenue has compounded at 5.09% a year since FY22. Operating margin was 36.70% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.
The stock trades at a PE of 85.60 against an industry PE of 36.42, with a return on equity of 15.32%. In the June 2026 quarter, revenue rose 24.32% to Rs 3,144 crore and net profit grew 65.50% to Rs 902 crore. The share price has gained 71.04% over five years and 38.43% over the past year. Foreign investors raised their holding from 19.39% in September 2025 to 20.38% in September 2026.
Torrent Pharma: 28.79% Profit CAGR Since FY22
Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.
In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026. The stock trades at a PE of 80.23 against an industry PE of 36.42, with a return on equity of 25.49%.
Polycab: 33.79% Profit CAGR Since FY22
Polycab India is a leading maker of wires and cables in India, with a growing fast-moving electrical goods business. It reported FY26 revenue of Rs 29,120.04 crore, up 28.76% year on year, and net profit of Rs 2,708.43 crore, up 32.41%. Net profit has compounded at 33.79% a year since FY22, while revenue has grown 24.06% a year. Operating margin was 14.69% in FY26. The debt-to-equity ratio is 0.02, which keeps interest costs low.
The stock trades at a PE of 42.66 against an industry PE of 49.96, below the sector average, with a return on equity of 22.25%. In the June 2026 quarter, revenue rose 38.90% to Rs 8,314.65 crore and net profit grew 32.84% to Rs 796.65 crore. The share price has gained 230.55% over five years. Foreign investors raised their holding from 11.44% in June 2025 to 19.00% in June 2026.
Revenue Growth Above Long-Term Average Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these revenue growth above long-term average stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | Latest Quarter Revenue Growth | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| Adani Ports | 40,854.36 | 12,782.03 | 26.16% | 20.55% | 23.90% | 65.67% |
| Divi’s Labs | 11,067 | 2,568 | 13.95% | 5.09% | 24.32% | 42.82% |
| Torrent Pharma | 13,886.15 | 2,138.18 | 20.34% | 12.38% | 56.29% | 33.73% |
| Polycab | 29,120.04 | 2,708.43 | 28.76% | 24.06% | 38.90% | 15.12% |
Check the Univest Screener for live data on these revenue growth above long-term average stocks
Institutional Holding in Adani Ports, Divi’s Labs, Torrent Pharma and Polycab
Institutional holding shows who is backing these revenue growth above long-term average stocks alongside the promoter. The table uses the latest reported quarter for each. Divi’s Labs has the deepest institutional backing, with FII and DII together holding 39.55% as of September 2026. Domestic institutions increased their holding over the past year in Torrent Pharma (from 9.28% to 12.87%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Adani Ports | 66.03% | 15.95% | 13.25% | 4.77% | September 2026 |
| Divi’s Labs | 51.88% | 20.38% | 19.17% | 8.58% | September 2026 |
| Torrent Pharma | 60.78% | 17.97% | 12.87% | 8.38% | July 2026 |
| Polycab | 61.46% | 19.00% | 7.62% | 11.92% | June 2026 |
Risks to Weigh in Revenue Growth Above Long-Term Average Stocks
Being careful with revenue growth above long-term average stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Past growth may not repeat.
- Share prices can move sharply in either direction.
- Valuation: Divi’s Labs trades at a PE of 85.60 against an industry PE of 36.42, so earnings need to keep growing to support the price.
- Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Revenue Growth Above Long-Term Average Stocks
Picking from revenue growth above long-term average stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (31.83 to 49.96) and ask whether the growth rate justifies any gap.
- Track net profit growth, the operating margin and the return on equity in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Adani Ports, Divi’s Labs, Torrent Pharma and Polycab live prices.
Conclusion
Among revenue growth above long-term average stocks, Adani Ports stands out for the lowest PE of the group at 30.89, Divi’s Labs for the strongest latest-quarter profit growth at 65.50%, Torrent Pharma for the highest return on equity at 25.49% and Polycab for the fastest profit growth, 33.79% a year since FY22. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing revenue growth above long-term average stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Revenue Growth Above Long-Term Average Stocks to Watch
Which are the best revenue growth above long-term average stocks to watch for multibagger potential?
Ans. Adani Ports, Divi’s Labs, Torrent Pharma and Polycab are the 4 names this list highlights, with market caps of Rs 4,05,286 crore, Rs 2,50,368 crore, Rs 1,72,983 crore and Rs 1,23,928 crore respectively. Adani Ports is notable for the lowest PE of the group at 30.89. Divi’s Labs stands out for the strongest latest-quarter profit growth at 65.50%. Torrent Pharma offers the highest return on equity at 25.49%. Polycab brings the fastest profit growth, 33.79% a year since FY22. These are watchlist names for revenue growth above long-term average stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Torrent Pharma a good stock for long-term investors?
Ans. Torrent Pharma has a return on equity of 25.49%, a PE of 80.23 against an industry PE of 36.42 and a market cap of Rs 1,72,983 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in revenue growth above long-term average stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Polycab become a multibagger from here?
Ans. Polycab has already gained 230.55% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in revenue growth above long-term average stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 33.79% a year since FY22, and FY26 revenue rose 28.76%. At a PE of 42.66 against an industry PE of 49.96, valuation should be checked against that growth before investing.
What is the market cap of Adani Ports, Divi’s Labs, Torrent Pharma and Polycab?
Ans. As of 28 October 2026, Adani Ports has a market cap of Rs 4,05,286 crore, Divi’s Labs has a market cap of Rs 2,50,368 crore, Torrent Pharma has a market cap of Rs 1,72,983 crore and Polycab has a market cap of Rs 1,23,928 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on revenue growth above long-term average stocks.
What are the risks of investing in revenue growth above long-term average stocks?
Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Divi’s Labs trades at a PE of 85.60 against an industry PE of 36.42, so earnings growth needs to hold up.
Why is Divi’s Labs trading at a PE of 85.60?
Ans. Divi’s Labs’ PE of 85.60 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 15.32% and latest-quarter profit growth of 65.50%, which also means the stock is more sensitive if growth slows. Investors in revenue growth above long-term average stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in Adani Ports, Divi’s Labs, Torrent Pharma and Polycab?
Ans. As of the latest reported quarter, FII and DII together hold 29.20% of Adani Ports (15.95% and 13.25%), 39.55% of Divi’s Labs (20.38% and 19.17%), 30.84% of Torrent Pharma (17.97% and 12.87%) and 26.62% of Polycab (19.00% and 7.62%). Rising institutional holding is a useful signal in revenue growth above long-term average stocks, though it should be read with earnings trends rather than on its own.
